BGB-30813: An In-Depth Analysis of BeiGene's First-in-Class DGKζ Inhibitor for Solid Tumor Immunotherapy

I. Executive Summary

BGB-30813 is a novel, orally administered, selective small-molecule inhibitor of Diacylglycerol Kinase Zeta (DGKζ), an investigational therapeutic agent under development by the global oncology company BeiGene.[1] The molecule is designed to enhance the body's immune response against cancer by targeting DGKζ, a critical intracellular immune checkpoint that negatively regulates T-cell activation. By inhibiting DGKζ, BGB-30813 is hypothesized to amplify T-cell-mediated anti-tumor immunity, particularly within the immunosuppressive tumor microenvironment (TME), and thereby overcome resistance to existing immunotherapies.[5]

Currently, BGB-30813 is being evaluated in a Phase 1a/1b first-in-human (FIH) clinical trial (NCT05904496). This study is assessing the drug's safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity both as a monotherapy and, critically, in combination with BeiGene's flagship anti-PD-1 antibody, tislelizumab (TEVIMBRA®).[8] The development of BGB-30813 is a direct reflection of BeiGene's corporate strategy to build a portfolio of innovative combination therapies centered around its cornerstone asset, tislelizumab, to address significant unmet needs in oncology, especially in patient populations refractory to current checkpoint inhibitors.[10]

The competitive landscape for DGK inhibition is rapidly evolving and is characterized by a key strategic divergence. While BeiGene and Bayer are pursuing selective DGKζ inhibition, other companies, including Incyte and Bristol Myers Squibb, are investigating dual DGKα/ζ inhibitors. The initial clinical data emerging from these parallel programs will provide critical validation for these competing biological hypotheses and will be crucial in determining the optimal path forward for this new class of immunotherapy agents.[6] The future of the BGB-30813 program hinges on the outcomes of the ongoing FIH trial, which must establish a favorable therapeutic window, provide clear pharmacodynamic evidence of target engagement, and demonstrate early signals of clinical activity, particularly in the tislelizumab combination arm.

II. Introduction to BGB-30813 and BeiGene's Immuno-Oncology Strategy

BGB-30813 is an investigational small-molecule drug candidate, administered orally in tablet form, being developed by BeiGene.[1] BeiGene is a global, science-driven biotechnology company with extensive operations in the United States, Europe, and China, and a sharp focus on developing and commercializing innovative oncology medicines.[1]

The development of BGB-30813 is deeply embedded within BeiGene's broader corporate and scientific strategy. The company's immuno-oncology (I-O) efforts are anchored by its humanized IgG4 anti-PD-1 monoclonal antibody, tislelizumab (TEVIMBRA®).[10] Tislelizumab is designed to minimize binding to Fc-gamma (

Fcγ) receptors on macrophages, which may otherwise compromise anti-tumor activity.[10] Having established tislelizumab as a foundational therapy with approvals in numerous indications and regions, BeiGene's strategy is to build a differentiated portfolio of novel combination regimens around it.[10] This approach is explicitly aimed at addressing the primary and acquired resistance to checkpoint inhibitor (CPI) monotherapy, which remains a major challenge in oncology. The company's pipeline includes over 20 distinct immuno-oncology and targeted molecules that could potentially be paired with tislelizumab, reflecting a commitment to exploring novel combination strategies to improve patient outcomes.[11]

The decision to advance BGB-30813 into a first-in-human trial that includes a tislelizumab combination arm from the very beginning is more than a scientific inquiry; it represents a clear strategic imperative.[8] For a company with a cornerstone asset like an anti-PD-1 antibody, the development of proprietary, synergistic combination partners is essential for long-term value creation and competitive positioning. A wholly-owned asset like BGB-30813 allows BeiGene to maintain full control over the clinical, regulatory, and commercial strategy of a unique combination therapy. This approach aims to create a high-value, differentiated regimen that could become a new standard of care, thereby protecting and expanding the commercial lifecycle of tislelizumab. The inclusion of a combination arm in the FIH trial signals a high degree of confidence in the preclinical safety profile and a desire to accelerate the generation of data to support the combination's development.

III. The Scientific Rationale: Targeting Diacylglycerol Kinase Zeta (DGKζ)

The DGK Family and T-Cell Signaling

The therapeutic rationale for BGB-30813 is rooted in the fundamental biology of T-cell activation. Diacylglycerol kinases (DGKs) are a family of ten distinct lipid kinase isozymes that serve as critical regulators of cellular signaling pathways.[7] Their primary function is to phosphorylate the second messenger diacylglycerol (DAG), converting it into phosphatidic acid (PA).[7]

In T-lymphocytes, DAG is transiently produced following the engagement of the T-cell receptor (TCR) with its cognate antigen presented by an antigen-presenting cell.[22] This burst of DAG is essential for activating downstream signaling cascades that drive the full T-cell response, including proliferation, cytokine production, and cytotoxic effector functions. Specifically, DAG recruits and activates key signaling proteins like Protein Kinase C theta (PKCθ) and Ras Guanyl Nucleotide Releasing Protein 1 (RasGRP1).[7] By metabolizing and thus terminating the DAG signal, DGK enzymes function as a physiological "brake" or a negative feedback loop, preventing T-cell hyperactivation and ensuring the immune response is appropriately controlled.[7]

DGKζ as an Intracellular Immune Checkpoint

Within the DGK family, the DGKζ and DGKα isoforms are the predominant forms expressed in T-cells and are the primary regulators of TCR-mediated DAG signaling.[7] Because it dampens T-cell activation from within the cell, independent of external ligands, DGKζ is increasingly referred to as a

ligand-independent, intracellular immune checkpoint.[6] This intracellular mechanism distinguishes it from well-known surface checkpoint receptors like PD-1, which require binding to ligands such as PD-L1 to transmit their inhibitory signals.

Of high relevance to oncology, research has shown that DGKζ is highly expressed in exhausted CD8+ T-cells isolated from the tumor microenvironment (TME).[6] This suggests that DGKζ is a key molecular driver of T-cell dysfunction within tumors, representing a prime target for therapeutic intervention.

Therapeutic Hypothesis for DGKζ Inhibition

The central therapeutic hypothesis for BGB-30813 is that selective inhibition of DGKζ will cause an accumulation of DAG within T-cells upon TCR stimulation. This sustained DAG signal is expected to lower the threshold required for T-cell activation and prolong pro-inflammatory signaling. This mechanism is anticipated to yield two major therapeutic benefits in the context of cancer:

1. Enhanced T-cell Priming: By lowering the activation threshold, DGKζ inhibition may enable the immune system to mount a response against weak or low-avidity tumor antigens that would otherwise be ignored, effectively turning immunologically "cold" tumors "hot".[6]
2. Overcoming TME-Mediated Immunosuppression: DGKζ inhibition has been shown preclinically to render T-cells resistant to the array of immunosuppressive factors prevalent in the TME, such as transforming growth factor-beta (TGFβ), prostaglandin E2 (PGE2), and adenosine.[6]

This mechanism is particularly well-suited to address the known modes of resistance to anti-PD-1/PD-L1 therapies. For tumors that lack a pre-existing T-cell infiltrate, a DGKζ inhibitor could help prime a new T-cell response. For tumors that are infiltrated by T-cells that have become functionally exhausted, inhibiting DGKζ could reinvigorate those cells, making them more responsive to the "release of the brakes" provided by a PD-1 inhibitor like tislelizumab. This potential for a dual impact makes the combination of a DGKζ inhibitor with a PD-1 inhibitor a highly rational and promising strategy.

The DGKζ vs. DGKα/ζ Debate: A Key Scientific and Strategic Divergence

A critical point of divergence has emerged in the field regarding the optimal targeting strategy for DGK enzymes in immunotherapy. This debate has led to two distinct development approaches by major pharmaceutical companies.

• The Case for Selective DGKζ Inhibition (BeiGene, Bayer, Astellas): A significant body of preclinical evidence suggests that DGKζ is the dominant isoform regulating CD8+ T-cell activity and anti-tumor immunity. In direct, head-to-head genetic studies in mouse models, DGKζ deficiency resulted in superior tumor growth control compared to DGKα deficiency.[24] Furthermore, a compelling safety rationale supports selectivity. While mice with a genetic knockout of only DGKζ are generally healthy, mice with a combined knockout of both DGKα and DGKζ develop severe, systemic, and lethal autoimmune disease.[31] This crucial finding suggests that selective DGKζ inhibition may offer a wider and more manageable therapeutic window compared to dual inhibition.
• The Case for Dual DGKα/ζ Inhibition (Incyte, Bristol Myers Squibb): In contrast, other preclinical research suggests that dual inhibition of both isoforms may be required for maximal or synergistic T-cell activation and anti-tumor effects.[13] The rationale for Incyte's dual inhibitor, INCB177054, is explicitly based on genetic data indicating that optimal T-cell activation requires the inhibition of both isoforms.[14]

The concurrent clinical development of both selective and dual DGK inhibitors represents a high-stakes clinical experiment. The initial safety and efficacy data from the Phase 1 trials of these competing molecules will be intensely scrutinized by the scientific and investment communities. The central question is whether the potential for enhanced efficacy with dual inhibition is offset by an unacceptable risk of on-target autoimmune toxicity. BeiGene's decision to pursue a selective DGKζ inhibitor represents a strategic bet on achieving a superior therapeutic index, prioritizing safety while still unlocking a potent anti-tumor immune response.

IV. Preclinical Evidence and Competitive Landscape

While specific preclinical data for BGB-30813 have not yet been publicly presented at major scientific congresses such as the American Society of Clinical Oncology (ASCO) or the European Society for Medical Oncology (ESMO), its expected profile can be reasonably inferred from its mechanism of action and the data available for its direct competitors.[1] BGB-30813 is anticipated to be a potent, selective, and orally bioavailable DGKζ inhibitor that enhances T-cell and NK-cell mediated tumor killing

in vitro, overcomes TME-derived immunosuppressive signals, and demonstrates T-cell-dependent monotherapy efficacy in syngeneic mouse models.[6] The most critical preclinical feature would be the demonstration of synergy with anti-PD-1/PD-L1 antibodies, leading to superior tumor growth inhibition compared to either agent alone.[6]

The competitive landscape for DGK inhibitors is nascent but highly active, with several key players pursuing distinct strategies.

Molecule	Company	Target(s)	Modality	Highest Phase	Key Public Data
BGB-30813	BeiGene	DGKζ	Small Molecule	Phase 1	FIH trial NCT05904496 active, not recruiting 8
BAY 2965501	Bayer	DGKζ	Small Molecule	Phase 1	Preclinical data at AACR 2023; FIH trial NCT05614102 ongoing 6
ASP1570	Astellas	DGKζ	Small Molecule	Phase 1/2	Phase 1 monotherapy data presented at ESMO 2024 46
INCB177054	Incyte	DGKα/ζ	Small Molecule	Phase 1	Preclinical data at AACR 2025; FIH trial NCT06231920 ongoing 14
BMS-986408	Bristol Myers Squibb	DGKα/ζ	Small Molecule	Preclinical	Disclosed in scientific publications 13
GS-9911	Gilead	DGKα	Small Molecule	Phase 1 (status unclear)	NCI-supported trial listed 48

Detailed Competitor Analysis

• Bayer's BAY 2965501: As the most direct competitor pursuing selective DGKζ inhibition, BAY 2965501 provides the best available proxy for BGB-30813's expected profile. Preclinical data presented at the American Association for Cancer Research (AACR) Annual Meeting in 2023 highlighted its high selectivity, oral availability, and ability to enhance T-cell reactivity. BAY 2965501 demonstrated efficacy in syngeneic mouse models and the ability to reactivate exhausted T-cells in vivo. Notably, preclinical toxicology was reported as favorable, with only low-grade gastrointestinal effects observed.[6] Its FIH trial (NCT05614102) commenced in November 2022, placing it on a development timeline similar to that of BGB-30813.[44]
• Incyte's INCB177054: This dual DGKα/ζ inhibitor embodies the alternative scientific hypothesis. Preclinical data presented at AACR 2025 showcased potent, subnanomolar inhibition of both isoforms. In mouse models, INCB177054 demonstrated significant tumor growth inhibition when combined with a PD-1 inhibitor.[14] Its FIH trial is also underway, setting the stage for a direct clinical comparison of the two approaches.[47]
• Astellas' ASP1570: This selective DGKζ inhibitor is particularly noteworthy as it is the first in its class to have publicly reported human clinical data. At the ESMO Congress 2024, Astellas presented results from the Phase 1 monotherapy dose-escalation portion of its trial involving 43 patients. The treatment demonstrated an acceptable safety profile, with the most common treatment-related adverse events (TRAEs) being diarrhea (48.8%), nausea (34.9%), and rash (25.6%), most of which were low-grade. Importantly, early signs of clinical activity were observed, with a disease control rate of 50% and one confirmed partial response.[46] The emergence of these positive human data from Astellas serves as a significant de-risking event for the entire DGKζ inhibitor class, including BGB-30813. It provides the first human proof-of-concept that selective DGKζ inhibition can be achieved with a manageable safety profile and can elicit anti-tumor activity. This raises the performance bar for both BeiGene and Bayer, who will now be expected to demonstrate at least comparable, if not superior, safety and efficacy profiles in their respective programs.

V. Clinical Development Program: The BGB-A317-30813-101 (NCT05904496) Trial

The clinical development of BGB-30813 is being initiated through a first-in-human, multicenter, open-label, Phase 1a/1b study.

Trial Parameter	Details
Trial ID	NCT05904496; EudraCT: 2023-503996-38; Other: BGB-A317-30813-101, CTR20233404, U1111-1290-6118, NCI-2024-00267 9
Full Title	A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors 8
Sponsor	BeiGene 9
Phase	Phase 1 9
Status	Active, not recruiting 9
Study Design	Open-label, non-randomized, parallel assignment, dose-escalation and dose-expansion study 8
Enrollment	Approximately 200 participants planned (44 currently listed) 9
Treatment Arms	Phase 1a (Dose Escalation):• Arm A: BGB-30813 Monotherapy• Arm B: BGB-30813 + TislelizumabPhase 1b (Dose Expansion):• BGB-30813 + Tislelizumab in selected tumor types 8
Primary Objectives	To evaluate safety and tolerability; to determine the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of BGB-30813 as monotherapy and in combination with tislelizumab 8
Secondary Objectives	To characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profiles; to assess preliminary anti-tumor activity (e.g., Overall Response Rate, Duration of Response) 8
Key Inclusion Criteria	• Histologically/cytologically confirmed advanced, metastatic, unresectable solid tumors• Failure of or intolerance to standard systemic therapy• ECOG performance status ≤ 1• At least one measurable lesion per RECIST v1.1• Prior checkpoint inhibitor (CPI) therapy is allowed 8
Key Exclusion Criteria	• Prior therapy targeting DGK• Active or uncontrolled symptomatic CNS metastases• Active autoimmune diseases or history of autoimmune diseases that may relapse• Systemic anticancer therapy within 21 days or 5 half-lives 8

Study Design and Objectives

The BGB-A317-30813-101 study is designed to first establish a safe and tolerable dose of BGB-30813 before expanding into specific patient populations to seek early signals of efficacy.[8] The primary objectives are centered on safety, including the characterization of the adverse event profile and the identification of any dose-limiting toxicities (DLTs) to establish the MTD and/or RP2D for subsequent studies.[8]

Treatment Arms and Target Population

The study's two-part design is standard for FIH oncology trials. The Phase 1a dose-escalation phase will enroll patients with a variety of advanced solid tumors into parallel arms to determine the safety of increasing doses of BGB-30813 both alone and with tislelizumab.[8] The

Phase 1b dose-expansion phase will then enroll larger cohorts of patients with specific "immune-sensitive" tumor types—such as non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastric cancer, and others—at the selected dose level, primarily in combination with tislelizumab, to gather more robust safety and preliminary efficacy data.[1]

A crucial aspect of the trial design is the inclusion of patients who have previously received CPI therapy.[8] This allows for the direct evaluation of BGB-30813's potential to overcome CPI resistance, a key element of its therapeutic hypothesis and a major area of unmet clinical need.

Biomarker Strategy

The explicit inclusion of pharmacodynamics (PD) as a key study objective indicates a comprehensive biomarker strategy is in place.[8] While specific assays are not detailed, the strategy can be inferred from the drug's mechanism of action and competitor programs. It will almost certainly include:

• Target Engagement: Measurement of downstream signaling molecules in the TCR pathway, such as phosphorylated ERK (pERK), in peripheral T-cells. This is essential to confirm that BGB-30813 is hitting its DGKζ target at clinically achievable concentrations and modulating the intended pathway.[43]
• Immune Modulation: Assessment of changes in T-cell and NK-cell activation markers (e.g., CD69), proliferation, cytokine production (e.g., IFNγ, IL-2), and markers of T-cell exhaustion (e.g., PD-1, TIM-3). These analyses will likely be performed on both peripheral blood and paired tumor biopsy samples to understand the drug's effects systemically and within the TME.[6]

For a novel immuno-oncology agent like BGB-30813, the generation of positive PD data from the initial dose-escalation cohorts represents a major value-inflection point. Demonstrating a clear, dose-dependent relationship between BGB-30813 administration and key immune biomarkers would provide early evidence of biological activity, significantly de-risking the program and building confidence in its therapeutic potential even before mature efficacy data, such as tumor response rates, become available.

VI. Anticipated Safety & Tolerability Profile

The primary safety concern for a T-cell activating agent like BGB-30813 is the potential for on-target immune-related adverse events (irAEs). Systemic T-cell activation, while therapeutically desirable for its anti-tumor effects, carries the risk of inducing autoimmune-like toxicities, such as rash, colitis, hepatitis, pneumonitis, or endocrinopathies. The profile of these potential irAEs may be similar to those observed with existing CPIs, though the underlying mechanism is distinct.

The decision by BeiGene to pursue a selective DGKζ inhibitor is strongly supported by a compelling safety rationale derived from preclinical genetic models. Studies have shown that while mice with a combined genetic knockout of both DGKα and DGKζ develop severe, lethal systemic autoimmune disease, mice with a knockout of only the DGKζ isoform are largely healthy, albeit with a hyper-responsive immune system.[31] This fundamental biological difference suggests that selective DGKζ inhibition may offer a significantly wider therapeutic window, allowing for potent immune activation with a more manageable risk of toxicity compared to dual DGKα/ζ inhibition.

This hypothesis is further supported by preclinical toxicology data for Bayer's selective DGKζ inhibitor, BAY 2965501, which were reported as tolerable with only low-grade gastrointestinal effects noted.[6] The initial clinical data from Astellas' selective DGKζ inhibitor, ASP1570, also showed a manageable safety profile in humans, with most TRAEs being low-grade and reversible.[46] The risk of toxicity will be carefully managed in the clinic through the standard 3+3 dose-escalation design of the Phase 1a trial, which is specifically designed to identify DLTs and establish a safe dose for further evaluation.[8]

VII. Future Outlook and Strategic Implications

The clinical development of BGB-30813 is at a nascent but critical stage. The program's trajectory will be determined by the data emerging from the ongoing NCT05904496 trial, which must address several key questions:

• Therapeutic Window: Can a dose be identified that provides clear evidence of immune activation, as measured by pharmacodynamic biomarkers, without inducing unacceptable or unmanageable immune-related toxicities? Establishing this balance is the most critical near-term hurdle.
• Pharmacodynamic Confirmation: Will the clinical data confirm target engagement and the hypothesized immune-modulating effects (e.g., T-cell activation, reversal of exhaustion markers) that were observed in preclinical models?
• Early Efficacy Signals: Will BGB-30813 show any signs of clinical activity as a monotherapy? More importantly, will the combination with tislelizumab demonstrate a promising efficacy signal, particularly in the key target population of patients who have previously failed or become resistant to CPI therapy?

The path to success for BGB-30813 lies in its ability to differentiate itself from the growing field of DGK inhibitors. A best-in-class profile would likely involve demonstrating a superior safety profile compared to dual DGKα/ζ inhibitors, favorable oral pharmacokinetic and pharmacodynamic properties that allow for convenient and effective dosing, and, most importantly, clear, synergistic efficacy with tislelizumab that is superior to what can be achieved with other combination strategies.

Assuming positive Phase 1 data, BeiGene will likely advance BGB-30813 into Phase 2 expansion cohorts focused on specific tumor types where a strong biological rationale exists and/or early signals of activity were observed, such as NSCLC, HNSCC, or gastric cancer.[1] The ultimate long-term vision would be a portfolio of registrational Phase 3 trials evaluating the tislelizumab plus BGB-30813 combination against the standard of care in major cancer indications.

The success of the BGB-30813 program would be transformative for BeiGene's solid tumor franchise. It would provide a wholly-owned, proprietary combination partner for its cornerstone asset, tislelizumab. This creates a significant competitive advantage by offering a novel, potentially superior regimen that competitors cannot easily replicate. Such a combination would not only have the potential to expand the market for tislelizumab into CPI-refractory patient populations but also to defend and strengthen its position in CPI-naïve settings, representing a substantial and durable long-term value driver for the company.

Works cited

1. BGB-30813 by BeiGene for Gastric Cancer: Likelihood of Approval, accessed June 16, 2025, https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-gastric-cancer-likelihood-of-approval/
2. BGB-30813 by BeiGene for Non-Small Cell Lung Cancer: Likelihood of Approval, accessed June 16, 2025, https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-non-small-cell-lung-cancer-likelihood-of-approval/
3. BGB-30813 | AbMole BioScience, accessed June 16, 2025, https://www.abmole.com/products/bgb-30813.html
4. www.pharmaceutical\-technology.com, accessed June 16, 2025, https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-non-small-cell-lung-cancer-likelihood-of-approval/#:~:text=BGB%2D30813%20overview&text=The%20drug%20candidate%20acts%20by,in%20the%20form%20of%20tablet.
5. Definition of diacylglycerol kinase zeta inhibitor BGB-30813 - NCI Drug, accessed June 16, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/diacylglycerol-kinase-zeta-inhibitor-bgb-30813
6. 926 BAY 2965501: a highly selective DGK zeta inhibitor for cancer immunotherapy, accessed June 16, 2025, https://jitc.bmj.com/content/11/Suppl_1/A1029
7. The Immunomodulatory Functions of Diacylglycerol Kinase ζ - Frontiers, accessed June 16, 2025, https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2016.00096/full
8. BGB-A317-30813-101 - Victorian Cancer Trials Link, accessed June 16, 2025, https://trials.cancervic.org.au/details/feed-cta-trial583
9. A Study of BGB-30813 Alone or in Combination With Tislelizumab in ..., accessed June 16, 2025, https://ctv.veeva.com/study/a-study-investigating-the-safety-tolerability-pharmacokinetics-and-preliminary-antitumor-activity
10. BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets, accessed June 16, 2025, https://ir.beigene.com/news/beigene-presentations-at-esmo-2023-demonstrate-robust-clinical-strategy-for-tislelizumab-as-monotherapy-and-in/0f23e032-e8d3-4403-82a6-ec4fef74ca30
11. BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab), accessed June 16, 2025, https://hkexir.beigene.com/news/beigene-strengthens-global-portfolio-and-regains-full-rights-from-novartis-for-anti-pd-1-antibody-tevimbra-tislelizumab/22284bb2-e89e-46f8-a5d5-db2faa80d1ea
12. 926 BAY 2965501: a highly selective DGK zeta inhibitor for cancer immunotherapy, accessed June 16, 2025, https://www.researchgate.net/publication/375130429_926_BAY_2965501_a_highly_selective_DGK_zeta_inhibitor_for_cancer_immunotherapy
13. Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor That Unleashes PD-1 Checkpoint and CAR T-Cell Immunotherapies - AACR Journals, accessed June 16, 2025, https://aacrjournals.org/cancerimmunolres/article/doi/10.1158/2326-6066.CIR-25-0156/762957/Discovery-of-BMS-986408-a-First-In-Class-Dual-DGK
14. Abstract 3789: INCB177054: A novel, potent, orally bioavailable DGKα/ζ dual inhibitor enhances T-cell function and demonstrates potent antitumor activity | Cancer Research - AACR Journals, accessed June 16, 2025, https://aacrjournals.org/cancerres/article/85/8_Supplement_1/3789/756960/Abstract-3789-INCB177054-A-novel-potent-orally
15. BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA's Leadership and Next-Generation Innovation - Business Wire, accessed June 16, 2025, https://www.businesswire.com/news/home/20250514394684/en/BeiGene-Showcases-Strength-of-Hematology-Portfolio-at-EHA-2025-with-New-Data-Highlighting-BRUKINSAs-Leadership-and-Next-Generation-Innovation
16. BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment - BeOne Medicines HKEX, accessed June 16, 2025, https://hkexir.beigene.com/news/beigene-announces-closing-of-amgen-global-strategic-oncology-collaboration-and-equity-investment/02b3e9d8-632b-4f33-a667-8d8359f0b2ce/
17. BeOne Pipeline, accessed June 16, 2025, https://beonemedicines.com/science/pipeline/
18. DGKζ Plays Crucial Roles in the Proliferation and Tumorigenicity of Human glioblastoma, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6743304/
19. What are DGK inhibitors and how do they work?, accessed June 16, 2025, https://synapse.patsnap.com/article/what-are-dgk-inhibitors-and-how-do-they-work
20. Diacylglycerol Kinases as Emerging Potential Drug Targets for a Variety of Diseases: An Update - PubMed Central, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4987324/
21. Diacylglycerol Kinase (DGK) Targeted Library - Life Chemicals, accessed June 16, 2025, https://lifechemicals.com/screening-libraries/targeted-and-focused-screening-libraries/kinase-general-libraries/kinase-targeted-libraries/diacylglycerol-kinase-dgk-targeted-library
22. Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer, accessed June 16, 2025, https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2016.00108/full
23. Small molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status - ResearchGate, accessed June 16, 2025, https://www.researchgate.net/publication/375150806_Small_molecule_inhibitors_for_cancer_immunotherapy_and_associated_biomarkers_-_the_current_status
24. DGKζ exerts greater control than DGKα over CD8 + T cell activity and tumor inhibition, accessed June 16, 2025, https://www.tandfonline.com/doi/full/10.1080/2162402X.2021.1941566
25. bay 2965501: a highly selective dgk zeta inhibitor for cancer immunotherapy - 926, accessed June 16, 2025, https://jitc.bmj.com/content/jitc/11/Suppl_1/A1029.full.pdf
26. 737 Optimal enhancement of anti-tumor T-cell immunity through the combined use of selective DGK zeta and DGK alpha inhibitors, accessed June 16, 2025, https://jitc.bmj.com/content/12/Suppl_2/A840
27. DGKζ exerts greater control than DGKα over CD8+ T cell activity and tumor inhibition - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8296965/
28. Abstract 936: Regulation of CD8+ T-cell function and antitumor activity by DGKα and DGKζ, accessed June 16, 2025, https://aacrjournals.org/cancerres/article/79/13_Supplement/936/637557/Abstract-936-Regulation-of-CD8-T-cell-function-and
29. DGKζ exerts greater control than DGKα over CD8+ T cell activity and tumor inhibition, accessed June 16, 2025, https://www.tandfonline.com/doi/abs/10.1080/2162402X.2021.1941566
30. DGKζ exerts greater control than DGKα over CD8 + T cell activity and tumor inhibition, accessed June 16, 2025, https://pubmed.ncbi.nlm.nih.gov/34350062/
31. B6.129X1-Dgkz tm1Gak /J - The Jackson Laboratory, accessed June 16, 2025, https://www.jax.org/strain/018861
32. DGKα and ζ Deficiency Causes Regulatory T-Cell Dysregulation, Destabilization, and Conversion to Pathogenic T-Follicular Helper Cells to Trigger IgG1-Predominant Autoimmunity - eLife, accessed June 16, 2025, https://elifesciences.org/reviewed-preprints/105212
33. Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization | Request PDF - ResearchGate, accessed June 16, 2025, https://www.researchgate.net/publication/371527794_Discovery_of_Potent_Dual-Inhibitors_of_Diacylglycerol_Kinases_Alpha_and_Zeta_Guided_by_Phenotypic_Optimization
34. INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function - Incyte Medical Information, accessed June 16, 2025, https://www.incytemi.com/document/Poster/AACR%202025%20-%20INCB177054%20DGK%20Oral%20Presentation.pdf
35. A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 - BeOne Medicines, accessed June 16, 2025, https://beonemedicines.com/clinical-trials/a-study-investigating-the-safety-tolerability-pharmacokinetics-and-preliminary-antitumor-activity-of-bgb-30813/
36. BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors - BioSpace, accessed June 16, 2025, https://www.biospace.com/press-releases/beigene-presents-pioneering-cancer-research-at-asco-2025-redefining-treatment-across-hematology-and-solid-tumors
37. BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors – BeOne Medicines NASDAQ, accessed June 16, 2025, https://ir.beonemedicines.com/news/beigene-presents-pioneering-cancer-research-at-asco-2025-redefining-treatment-across-hematology-and-solid/64ab219f-7f52-447b-9504-232e70446dc4
38. A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors - NCI, accessed June 16, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-00267
39. Poster - ASCO Annual Meeting, accessed June 16, 2025, https://meetings.asco.org/abstracts-presentations/244439/poster
40. BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024, accessed June 16, 2025, https://ir.beonemedicines.com/news/beigene-to-present-clinical-and-preclinical-data-from-broad-portfolio-and-pipeline-at-aacr-annual/b5a8ec19-ca85-443c-800a-2471310d6b11
41. Poster - ASCO Meeting Program Guide, accessed June 16, 2025, https://meetings.asco.org/abstracts-presentations/233485/poster
42. Arbele presented 5 posters in American Association of Cancer Research (AACR) 2024, accessed June 16, 2025, https://www.arbelebio.com/post/arbele-presented-5-posters-in-aacr2024
43. 2023-0046e.rtf - Bayer Global, accessed June 16, 2025, https://www.bayer.com/media/download/831538f7-2d80-4a10-9fbc-14dd55d8f4b3/2023-0046e.rtf
44. BAY-2965501 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed June 16, 2025, https://synapse.patsnap.com/drug/065bc031ce3f4fe08135245078432639
45. Abstract ND04: BAY 2965501: A highly selective DGK- ζ inhibitor for cancer immuno-therapy with first-in-class potential - AACR Journals, accessed June 16, 2025, https://aacrjournals.org/cancerres/article/83/7_Supplement/ND04/727035/Abstract-ND04-BAY-2965501-A-highly-selective-DGK
46. Phase I/II trial of ASP1570, a novel diacylglycerol kinase ζ inhibitor, in patients with advanced solid tumors - ESMO Congress 2024 | OncologyPRO, accessed June 16, 2025, https://oncologypro.esmo.org/meeting-resources/esmo-congress-2024/phase-i-ii-trial-of-asp1570-a-novel-diacylglycerol-kinase-z-inhibitor-in-patients-with-advanced-solid-tumors
47. A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors - ClinicalTrials.Veeva, accessed June 16, 2025, https://ctv.veeva.com/study/a-study-to-evaluate-incb177054-in-participants-with-select-advanced-or-metastatic-solid-tumors
48. Clinical Trials Using DGK-alpha Inhibitor GS-9911 - NCI, accessed June 16, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/dgk-alpha-inhibitor-gs-9911
49. Abstract ND04: BAY 2965501: A highly selective DGK- ζ inhibitor for cancer immuno-therapy with first-in-class potential | Request PDF - ResearchGate, accessed June 16, 2025, https://www.researchgate.net/publication/371458260_Abstract_ND04_BAY_2965501_A_highly_selective_DGK-_z_inhibitor_for_cancer_immuno-therapy_with_first-in-class_potential
50. BAY 2965501 | DGKζ Inhibitor - MedchemExpress.com, accessed June 16, 2025, https://www.medchemexpress.com/bay-2965501.html
51. Pipeline Overview, accessed June 16, 2025, https://www.bayer.com/sites/default/files/ph-rd-pipeline-2023-08-final-new.pdf
52. Pharmaceuticals, accessed June 16, 2025, https://www.bayer.com/sites/default/files/ph-rd-pipeline-2025-05-02-final.pdf
53. WO2024108100A1 - Heteroaryl fluoroalkenes as dgk inhibitors - Google Patents, accessed June 16, 2025, https://patents.google.com/patent/WO2024108100A1/en
54. A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors - ClinConnect, accessed June 16, 2025, https://clinconnect.io/trials/NCT05904496